Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Trading Up 30.9 %

Shares of EVGN stock opened at $1.27 on Friday. Evogene has a 1 year low of $0.95 and a 1 year high of $9.00. The firm’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $1.63. The firm has a market capitalization of $6.81 million, a P/E ratio of -0.28 and a beta of 1.37.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The business had revenue of $1.61 million during the quarter, compared to analyst estimates of $3.63 million. During the same quarter in the prior year, the business earned ($1.30) earnings per share.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.